Month: March 2021

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

Written by Customer Service on March 29, 2021. Posted in Public Companies.

SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus. The longitudinal study will further evaluate the emergence of biomarkers that are known indicators for the development of lupus, rheumatoid arthritis and other autoimmune diseases. This effort will assess the emergence of these biomarkers in mild/moderate COVID patients, among several critical patient groups, including those treated with dexamethasone. Dr. Ignacio...

Greiðslumiðlunin Hringur ehf. : Ársreikningur 31.12.2020

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Meðfylgjandi er ársreikningur Greiðslumiðlunarinnar Hrings ehf. 31.12.2020 Samþykktur á stjórnarfundi í dag 29. mars 2021. ViðhengiGreiðslumiðlunin Hringur ehf – Ársreikningur 2020 – FIN

SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2021. Posted in Public Companies.

FDA accepted SCYNEXIS’ New Drug Application (NDA) for oral ibrexafungerp for the treatment of vaginal yeast infections, conditionally approved the brand name BrexafemmeTM, and granted priority review with a PDUFA target action date of June 1, 2021 SCYNEXIS partnered with Amplity Health, a leading global contract commercialization organization, in connection with anticipated U.S. launch of Brexafemme in the second half of 2021, with a portion of Amplity’s direct fees deferred SCYNEXIS out-licensed the rights to ibrexafungerp for the Greater China region to Hansoh Pharma, resulting in a $10 million upfront payment and the potential for up to $112 million in additional milestones plus royalties on sales Enrollment is complete in the Phase 3 CANDLE study of oral ibrexafungerp for the prevention of recurrent vaginal yeast infections; last-patient...

Healthier Choices Management Corp. Announces Re-Launching of its Vitamins and Supplements Online Store at TheVitaminStore.com

Written by Customer Service on March 29, 2021. Posted in Public Companies.

HOLLYWOOD, FL, March 29, 2021 (GLOBE NEWSWIRE) — Healthier Choices Management Corp. (OTC Pink: HCMC) Today Announced the Re-Launching of its Vitamins and Supplements Online Store at TheVitaminStore.com. This online store was originally purchased as part of the acquisition of the HCMC’s 3 Paradise Health & Nutrition branded stores in Melbourne, FL. HCMC will be offering select national brands and, for the first time online, Ada’s high quality brand of Vitamins and Supplements, previously sold only in Ada’s Natural Market, the Company’s organic grocery store located in Fort Myers, FL. “Management has recognized and is grateful for both the national attention that HCMC has received over the past several months, and for the very vocal support of its shareholder base, which is now over 306,000 shareholders strong. This has provided...

F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2021. Posted in Earnings Releases And Operating Results.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 29, 2021 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces 2020 full-year financial results and provides corporate update. 2020 was a year of transformation for F-star. The Company successfully listed on NASDAQ and advanced multiple programs into the clinic. F-star also presented Phase 1 data on its most advanced program FS118, and dosed patients in two additional clinical trials with FS222 and FS120. The Company continued to deliver on its long-term collaborations and ended the year with a total of four clinical stage programs, and a robust pipeline generated from its unique tetravalent bispecific platform...

NV5 Acquires Geodynamics, Expanding Deep-Water Geospatial Capabilities

Written by Customer Service on March 29, 2021. Posted in Mergers And Acquisitions.

HOLLYWOOD, Fla., March 29, 2021 (GLOBE NEWSWIRE) — NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of compliance, technology, and engineering consulting solutions, announced today that it has acquired Geodynamics LLC (“Geodynamics”), a provider of sonar-based, deep-water geospatial solutions. Geodynamics’ clients include the National Oceanic and Atmospheric Administration (NOAA), the U.S. Army Corps of Engineers, the U.S. Navy, state and local agencies, and port and transportation authorities. Geodynamics, headquartered in Morehead City, North Carolina, will operate within NV5’s Geospatial vertical, adding full-ocean depth hydrographic and geophysical surveying to NV5’s topographic and nearshore geospatial capabilities. The $42 million acquisition, which includes an earn out provision, was made with a combination...

8th Avenue Food & Provisions, Inc. to Acquire Ronzoni® Dry Pasta Brand from Riviana Foods, a subsidiary of Ebro Foods, S.A.

Written by Customer Service on March 29, 2021. Posted in Mergers And Acquisitions.

ST. LOUIS, March 29, 2021 (GLOBE NEWSWIRE) — 8th Avenue Food & Provisions, Inc. (“8th Avenue”) today announced that it has agreed to acquire the Ronzoni dry pasta brand and a dry pasta manufacturing facility located in Winchester, Virginia from Riviana Foods Inc. Ronzoni is a 100-year-old brand with a comprehensive portfolio across traditional and value-added pasta. Scott McNair, Chief Executive Officer of 8th Avenue, said, “We are looking forward to welcoming the Ronzoni brand to our team, a pioneer and leader in the pasta category. With its highly on-trend, versatile product offering, state-of-the art facility, and impressive customer base, Ronzoni has a strong foundation from which to build on its leading market presence. Together with the Ronzoni team, we look forward to driving further growth and scale by delivering innovative...

Limestone Announces Proposed Acquisition of Ebbtide Holdings, LLC and Offering of Up to $17 Million of Convertible Debentures

Written by Customer Service on March 29, 2021. Posted in Mergers And Acquisitions.

COLLINGWOOD, Ontario, March 29, 2021 (GLOBE NEWSWIRE) — The Limestone Boat Company Limited (“Limestone” or the “Company”) (TSXV: BOAT) has entered into a Letter of Intent (the “LOI”) to purchase 100% of Ebbtide Holdings, LLC (“Ebbtide”) of White Bluff, Tennessee (the “Acquisition”). The purchase price of the Acquisition is comprised of USD$5,280,000 in cash and the assumption and payment of USD$4,043,800 Ebbtide’s existing debt. The Acquisition and working capital will be financed through the issuance of up to $17.0 million of convertible debentures of the Company through a non-brokered private placement (the “Offering”). Acquisition of Ebbtide Ebbtide manufactures the Aquasport and Boca Bay brands for their own account, as well as the Limestone line-up under contract for Limestone. The Acquisition will allow for the expanded production...

Regency Centers Invites You to Join Its First Quarter 2021 Earnings Conference Call

Written by Customer Service on March 29, 2021. Posted in Public Companies.

JACKSONVILLE, Fla., March 29, 2021 (GLOBE NEWSWIRE) — Regency Centers Corporation (The “Company”) (NASDAQ: REG) will announce its First Quarter 2021 earnings results on Thursday, May 6, 2021, after the market closes. The Company’s earnings release and supplemental information package will be posted on the Investor Relations section of the Company’s website – investors.regencycenters.com. The Company will host an earnings conference call on Friday, May 7, 2021, at 11:00 a.m. ET.First Quarter 2021 Earnings Conference CallDate: Friday, May 7, 2021Time: 11:00 a.m. ETDial#: 877-407-0789 or 201-689-8562Webcast: investors.regencycenters.comReplay Webcast Archive: Investor Relations page under Webcasts & Presentations About Regency Centers Corporation (NASDAQ: REG) Regency Centers is the preeminent national owner,...

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

Written by Customer Service on March 29, 2021. Posted in Public Companies.

– Pivotal data from lead program, ADAIR, expected in second half 2021 – Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 – Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple drugs and indications PHILADELPHIA, PA,, March 29, 2021 (GLOBE NEWSWIRE) — Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today reported its financial results for the full year 2020. Additionally, the Company provided an update on its development programs, ADAIR and ADMIR, which leverage the Company’s proprietary technology that is designed to resist manipulation for snorting...

Month: March 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals